OCA
ADCT icon

Octagon Capital Advisors’s ADC Therapeutics ADCT Stock Holding History

Octagon Capital Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,000
Closed -$145K – 33
2022
Q3 		$145K Buy
+30,000
New +$217K 0.03% 35

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Octagon Capital Advisors's ADCT Position: Q4 2022 in Review

Octagon Capital Advisors sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 30,000 shares — an estimated $145K sold.

Octagon Capital Advisors first reported a position in ADCT in Q3 2022 and held it in 1 quarter. The position peaked at $145K in Q3 2022. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

  • Octagon Capital Advisors reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 30,000 ADC Therapeutics shares in Q4 2022, an estimated $145K.
  • Octagon Capital Advisors first reported a position in ADC Therapeutics in Q3 2022 and held it in 1 quarter.
  • Octagon Capital Advisors's ADC Therapeutics position peaked at $145K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on Octagon Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.